Biotech Ardelyx Beats Shareholder Suit Over Kidney Drug

By Katryna Perera · March 18, 2024, 7:23 PM EDT

Biotechnology company Ardelyx Inc. has for now beaten a shareholder class action alleging the company and its top brass made false and misleading statements about regulatory approval of Ardelyx's drug for...

To view the full article, register now.